If You Invested in Perrigo Co Plc (PRGO)

Perrigo Company plc (NYSE: PRGO) is described in its public communications as a leading pure-play self-care and consumer health company. It focuses on over-the-counter (OTC) self-care products and health and wellness solutions that consumers can use without a prescription. According to the company, its offerings are designed to support proactive self-management of conditions that do not require direct medical supervision.

Perrigo states that it has over a century of experience in consumer health and that it serves consumers primarily in North America and Europe. In its press releases, the company characterizes itself as a pioneer in the OTC self-care market, emphasizing accessibility and choice for consumers across different molecules, dosage forms and value tiers. This positioning reflects a focus on making self-care products available at multiple price points.

The company’s business model, as described in its own materials, is built around complementary businesses. Cash-generative store brand private label offerings are used to fund investments in its branded portfolio. Perrigo highlights several brands in this context, including Opill®, Mederma®, Compeed®, EllaOne® and Jungle Formula®. These brands are cited by the company as examples of its consumer self-care focus in areas such as women’s health, skin care and other OTC categories.

Perrigo organizes its operations around consumer self-care. In its financial reporting, it refers to two main segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment covers its consumer self-care activities in the Americas, while CSCI covers international markets. Within these segments, the company reports on categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements (VMS), Women’s Health, Skin Care, Oral Care and Healthy Lifestyle, among others, as reflected in its earnings releases.

In recent disclosures, Perrigo has emphasized its OTC store brand business in North America, noting share gains in multiple store brand categories. The company also reports that it markets national brands in international markets, with brands such as Compeed®, Solpadeine®, Coldrex® and EllaOne® mentioned in historical descriptions of its European and other international activities. Perrigo has described its model as spanning more molecules at more price points, which it associates with resilience across different market conditions.

Perrigo has also communicated a strategic framework it calls the “Three-S” plan – Stabilize, Streamline and Strengthen. In its earnings releases, the company links this plan to efforts to improve organizational agility, focus its portfolio and support long-term business performance. Related to this, Perrigo has launched Project Energize, described as a global investment and efficiency program intended to support its “One Perrigo” growth strategy, increase organizational agility and reset its selling, general and administrative (SG&A) expense base. The company has stated that Project Energize is expected to deliver significant annualized pre-tax savings by the end of 2026, with a portion of those savings reinvested.

Portfolio focus is another theme in Perrigo’s communications. The company notes that it previously divested animal health and generic pharmaceuticals businesses to concentrate on consumer self-care. More recently, it has announced an agreement to sell its Dermacosmetics branded business in certain European markets and has disclosed that this transaction is expected to close subject to customary conditions. Perrigo has also indicated that it is conducting a strategic review of its Oral Care business and has initiated a strategic review of its infant formula business, stating that the infant formula business represents a significant portion of its Nutrition category but less than 10% of total annual net sales. These reviews are described as part of the company’s effort to align its portfolio with its consumer health OTC focus and capital allocation priorities.

In its own description, Perrigo highlights that its infant formula operations have stabilized and that it remains a large-scale U.S. store brand and contract manufacturer in that category with a near-term innovation pipeline. At the same time, the company notes that external conditions in the infant formula industry have changed and that it is evaluating the strategic fit of this business with its broader OTC consumer health portfolio.

Perrigo’s public statements also emphasize store brand market share gains and performance in key OTC categories. In recent quarters, the company has reported gaining dollar, unit and volume share in several OTC store brand categories in the Americas, and share gains in key brands in international markets. It links these trends to its focus on accessible self-care solutions across value tiers.

From a corporate structure perspective, Perrigo Company plc is incorporated in Ireland, as indicated in its SEC filings, and its ordinary shares trade on the New York Stock Exchange under the symbol PRGO. The company files periodic and current reports with the U.S. Securities and Exchange Commission, including Form 10-K annual reports, Form 10-Q quarterly reports and Form 8-K current reports for material events.

Overall, Perrigo presents itself as a consumer health and self-care company centered on OTC products, with a dual focus on store brand private label offerings and branded products, and with an active program of portfolio management and cost-efficiency initiatives.